NGNicholas A. Gherardin

Nicholas A. Gherardin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicholas A. Gherardin has a total of 929 co-authors. Here are the top co-authors by number of shared publications:

  • Dale I. Godfrey

    Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity at the University of Melbourne, Melbourne, Victoria, Australia

    31 shared publications
  • Adam P. Uldrich

    Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia

    18 shared publications
  • Jamie Rossjohn

    Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia

    18 shared publications
  • Dale I. Godfrey

    Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Victoria 3000, Australia

    15 shared publications
  • James McCluskey

    Department of Microbiology & Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia

    12 shared publications
  • Daniel G. Pellicci

    Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia

    11 shared publications

Latest Publications

  • Conserved T cell receptor usage underpins recognition of CD1c presenting a mycobacterial lipid

    by Thinh-Phat Cao, Caroline Soliman, Samuel J. Redmond, Tori Tappen, Jade Kollmorgen, Qiji Geng, D. Branch Moody, Thomas J. Scriba, Adam P. Uldrich, Adriaan J. Minnaard, et al.

    The mechanism by which αβ T cell receptors (TCRs) recognize mycobacterial lipids presented by CD1 family members is not well understood. We used CD1c tetramers loaded with the mycobacterial phosphomycoketide (PM) or mannosyl-PM to isolate T cells from healthy blood donors and individuals from a tuberculosis (TB)-endemic region of South Africa, with higher frequencies observed in individuals from the TB-endemic region. High-throughput analysis of >200 paired CD1c–mycoketide tetramer+ αβTCRs identified a conserved TCR motif, encoded by TRBV4-1 or TRBV7-9 variable region genes in greater than half of TCRs sequenced. A cryo-EM structure of a TRBV7-9+ TCR in complex with CD1c-PM demonstrated that the TCR bound to the A′-side of CD1c, directly contacting the phospholipid antigen and F′-portal residues. Analysis of multiple T cell clones interacting with CD1c mutants suggested that this TCR docking mode is representative of the larger TRBV7-9+ T cell population. Collectively, this study provides insight into mycobacterial lipid antigen recognition by αβ T cells restricted to CD1c.

  • Specific targeting of MR1-antigen complexes using nanobodies

    by Hisham S. Hussain, Samuel J. Redmond, Wael Awad, Calvin Xu, Caroline Soliman, Huimeng Wang, Yuyang Zhang, Lisa Ciacchi, Alexis P. Gonzalez, Jeffrey Y. W. Mak, et al.

    T cell receptor mimic (TCRm) antibodies that bind peptide–human leukocyte antigen complexes have great therapeutic potential. Major histocompatibility complex class I–related protein 1 (MR1) exhibits limited polymorphism and presents conserved metabolites, such as 5-OP-RU, derived from microbial riboflavin biosynthesis. Whether antibodies targeting such MR1–5-OP-RU complexes can be generated remains unclear. Using yeast display technology, nanobodies with high affinity toward the MR1–5-OP-RU complex were generated. These nanobodies can bind both mouse and human MR1–5-OP-RU and inhibit mucosal-associated invariant T (MAIT) cell responses to 5-OP-RU and bacterial challenge, demonstrating in vitro and in vivo bioactivity. We also solved the crystal structures of the lead nanobody in complex with MR1 antigens and demonstrated that the nanobody cobound MR1 and 5-OP-RU, akin to a TCRm antibody. Last, we engineered bispecific antibodies targeting both MR1–5-OP-RU and CD3 that drive broad T cell killing of bacterially infected cells as well as tumor cells treated with 5-OP-RU, providing evidence for immune redirection via MR1-targeting TCRm-based nanobodies.

  • Open Access

    Conserved T cell receptor usage underpins recognition of CD1c presenting a mycobacterial lipid

    by Thinh-Phat Cao, Caroline Soliman, Samuel J. Redmond, Tori Tappen, Jade Kollmorgen, Qiji Geng, D. Branch Moody, Thomas J. Scriba, Adam P. Uldrich, Adriaan J. Minnaard, et al.

    The mechanism by which T cell receptors (TCR) recognise mycobacterial lipids presented by CD1 family members not well understood. We used CD1c tetramers loaded with the mycobacterial phosphomycoketide (PM) or mannosyl-PM (MPM) to isolate T cells ex vivo in healthy blood donors and in individuals from a tuberculosis (TB)-endemic region of South Africa, with higher frequencies observed in individuals from the TB-endemic region. High throughput analysis of >200 paired CD1c-mycoketide tetramer + αβTCRs identified a conserved TCR motif, encoded by TRBV4-1 or TRBV7-9 variable region genes in greater than half of TCRs sequenced. A cryo-EM structure of a TRBV7-9 + TCR in complex with CD1c-PM demonstrated that the TCR bound to the F’ side of CD1c, directly contacting the phospholipid antigen and F’-portal residues. Analysis of multiple T cell clones interacting with CD1c mutants suggested that this TCR docking mode is representative of the larger TRBV7-9 + T cell population. Collectively, this study provides insight into mycobacterial lipid-antigen recognition by CD1c-restricted T cells. Summary: Cao and Soliman et al study CD1c-restricted human T cells that recognize mycobacterial phosphomycoketide lipids, where they are shown to be more frequent in blood a TB-endemic region. The authors describe a strong TCR-β repertoire bias and use cryoEM to provide a high-resolution structure of an archetypal TCR engaging CD1c in complex with a mycobacterial lipid.

  • Open Access

    Autoimmune-like CD8⁺ T Cell Responses Drive Atherosclerotic Plaque Instability and Predict Cardiovascular Events

    by Jonathan Noonan, Nicholas Borcherding, Sander W. van der Laan, Nicholas A. Gherardin, Moustafa I Morsy, Joshua I. Gray, Lisa M. Domke, Anna M.D. Watson, Angela Huang, Anastasia Barbaro-Wahl, et al.

    Background and aims: Atherosclerotic plaque rupture is a major cause of myocardial infarction and stroke. However, the precise drivers of plaque destabilisation remain elusive. We hypothesised that antigen-driven, autoimmune-like T cell responses are central to the destabilisation and rupture of atherosclerotic plaques. Methods: To dissect T cell responses specifically in unstable compared to stable plaques, we leveraged near-infrared autofluorescence (NIRAF) imaging–guided dissection of human carotid plaques. We also used our tandem stenosis model reflecting plaque instability as seen in patients to differentiate between unstable and stable plaques in mice. To explore T cell involvement, we studied T cell differentiation states and T cell receptor (TCR) repertoires by single-cell multi-omics. Then, testing if antigen-driven CD8 + T cell responses drive plaque instability in mice, we applied a combination of AAV8-PCSK9-induced atherosclerosis, tandem stenosis and TCR transgenic mice. Finally, we leveraged data from the AtheroExpress Biobank Study to link T cell immunity to histology-defined instability and cardiovascular outcomes. Results: T cell responses in unstable versus stable atherosclerosis were distinct. Unstable human plaques contained highly expanded, autoimmune-like CD8⁺ T cells with markedly increased cytotoxic signatures, reduced exhaustion and distinct clonal repertoires compared to stable regions. Most plaque CD8⁺ T cells exhibited a pronounced tissue-resident transcriptional program. Moreover, the transcriptional signature of these plaque resident T cells was distinct from multiple other human tissues. Autoimmune-like cytotoxic and tissue-resident CD8 + T cell responses were also evident in murine atherosclerosis, where restricting the activation of antigen-driven CD8 + T cells prevented plaque destabilisation. Importantly, analysis of carotid endarterectomy samples from >1000 patients identified that intraplaque cytotoxic CD8⁺ T cell gene signatures strongly correlated with histological instability and predicted future strokes. Conclusions: Integrated human, murine and clinical analyses demonstrate that autoimmune-like, cytotoxic CD8⁺ T cell responses are central drivers of plaque instability and major cardiovascular events. Targeting pathogenic CD8⁺ T cell responses may thus offer a compelling immunomodulatory strategy to stabilise plaques and reduce the risks of stroke and myocardial infarction. Graphical Key Question: Rupture of unstable atherosclerotic plaques is a typical cause of myocardial infarction and stroke. To understand the underlying cause and to prevent plaque rupture, we addressed the central hypothesis that autoimmune-like T cell responses drive plaque destabilisation and rupture. Key Findings: CD8 + T cells are clonally expanded with increased cytotoxic signatures in unstable versus stable plaques (mice and humans) and require antigen recognition to drive plaque instability. Cytotoxic CD8 + T cell signatures in excised plaques correlate with increased future cardiovascular events. Take Home Message: Autoimmune-like adaptive immune reactions, dominated by CD8 + T cells, are a major driver of plaque instability/rupture. Therefore, targeting pathogenic CD8⁺ T cell responses offers a compelling immunomodulatory strategy to stabilise plaques and reduce the risk of myocardial infarction and stroke.

  • Open Access

    Specific targeting of MR1-antigen complexes using nanobodies

    by M.H. Shakir Hussain, Samuel J. Redmond, Wael Awad, Calvin Xu, Caroline Soliman, Lisa Ciacchi, Alexis P. Gonzalez, Jeffrey Y. W. Mak, David P. Fairlie, James McCluskey, et al.

    T cell receptor mimic (TCRm) antibodies and nanobodies that specifically bind peptide-HLA complexes have great therapeutic potential, as they can target polymorphic HLA on tumour cells furnishing peptides derived from tumour-associated antigens. MR1 is an MHC class-I-like molecule that exhibits limited polymorphism that binds and presents conserved metabolites, such as 5-OP-RU, derived from microbial riboflavin biosynthesis. Whether antibodies targeting such MR1-5-OP-RU complexes can be generated remains unclear. Using yeast display technology and in vitro affinity maturation, a nanobody with high affinity and fine specificity toward MR1-5-OP-RU complex was generated. These nanobodies bind both mouse and human MR1-5-OP-RU and inhibited MAIT cell responses to 5-OP-RU in vitro and in vivo demonstrating therapeutic potential. Moreover, we provide a molecular basis underpinning the fine specificity of these nanobodies, solving the crystal structures of MR1 in complex with either 5-OP-RU or Ac-6-FP. Here, the nanobody co-bound MR1 and 5-OP-RU, akin to a TCRm antibody. Moreover, we engineer bispecific antibodies targeting both MR1-5-OP-RU and CD3, that drive broad T cell killing of bacterially-infected cells as well as tumour cells treated with 5-OP-RU, thereby providing proof-of-principle for targeting the MR1 molecule with with TCRm-based nanobodies. One Sentence Summary: We report the development of a nanobody targeting MR1-5-OP-RU complex and demonstrate its utility to modulate MAIT cells responses, and as a bispecific engager.

  • Open Access

    Sideways lipid presentation by the antigen-presenting molecule CD1c

    by Thinh-Phat Cao, Guan-Ru Liao, Tan-Yun Cheng, Yanqiong Chen, Laura Ciacchi, Thomas S. Fulford, Rachel Farquhar, Jade Kollmorgen, Jacob A. Mayfield, Adam P. Uldrich, et al.

    For the MHC, MR1 and CD1 systems, antigen recognition involves contact of the membrane distal surfaces of both the αβ T cell receptor (TCR) and the antigen-presenting molecule. Whether other antigen display mechanisms by antigen-presenting molecules operate remains unknown. Here, we report mass spectrometry analyses of endogenous lipids captured by CD1c when bound to an autoreactive αβ TCR. CD1c binds twenty-six lipid species with bulky headgroups that cannot fit within the tight TCR-CD1c interface. We determined the crystal structures of CD1c presenting several gangliosides, revealing a general mechanism whereby two lipids, rather than one, are bound in the CD1c cleft. Bulky lipids are oriented sideways so that their polar headgroups protrude laterally through a side portal of the CD1c molecule - an evolutionarily conserved structural feature. The sideways-presented ganglioside headgroups do not hinder TCR binding and so represent a mechanism that allows autoreactive TCR recognition of CD1c. In addition, ex vivo studies showed that the sideways-presented gangliosides can also represent TCR recognition determinants. These findings reveal that CD1c simultaneously presents two lipid antigens from the top and side of its cleft, a general mechanism that differs markedly from other antigen-presenting molecules.


  • Open Access

    The antigen-presenting molecule MR1 binds host-generated riboflavin catabolites

    by Mohamed R. Abdelaal, Jieru Deng, Mitchell P. McInerney, Emi Ito, Anthony W. Purcell, Sho Yamasaki, Jose A. Villadangos, Hamish E.G. McWilliam, Nicholas A. Gherardin, Jamie Rossjohn, et al.

    MHC class I–related protein (MR1) presents vitamin B–based antigens (Ags) to mucosal-associated invariant T (MAIT) cells. While microbial riboflavin (RF) precursors are well-documented MR1 ligands, it is unclear whether host-generated RF catabolites influence MR1 immunity. Here, we report that RF catabolites, including 10-formylmethylflavin (FMF), lumichrome, lumiflavin, and alloxazine, bind to MR1 with moderate affinity, while RF itself binds weakly. In contrast to the MR1-upregulating microbial RF precursors, RF catabolites reduced the surface level of MR1 by inducing its retention in the endoplasmic reticulum and inhibiting exit. These RF catabolites weakly competed with vitamin B–based Ags for MR1 binding, thereby selectively inhibiting MAIT activation. The crystal structures of MR1 with RF, FMF, lumiflavin, and lumichrome show binding in the A′-pocket of MR1. Here, lumichrome formed a “flavin bond” covalent interaction with MR1-Lys43 differing from the typical Schiff base. Collectively, we identified three-ringed isoalloxazines that bind MR1 and reduce surface levels, suggesting a potential role in dampening MAIT cell immunity.


  • Open Access

    WITHDRAWN: γδ T cells modulate anti-tumor immunity in small cell lung cancer

    by Jin Ng, Yue You, Tina Z. Zhang, Jonas B. Hess, Sarah A. Best, Alex Caneborg, Marcel Schmiel, Dale I. Godfrey, Yin Wu, Richard W. Tothill, et al.

    Withdrawal statement: This manuscript and associated files have been removed owing to the presence of confidential information. The paper has been published and is available at doi: 10.1016/j.ccell.2026.08.015


  • Open Access

    Direct recognition of an intact foreign protein by an αβ T cell receptor

    by Catarina F. Almeida, Benjamin S. Gully, Claerwen M. Jones, Lukasz Kedzierski, Sachith D. Gunasinghe, Michael T. Rice, Richard Berry, Nicholas A. Gherardin, Trang T. Nguyen, Yee-Foong Mok, et al.

    αβ T cell receptors (αβTCRs) co-recognise antigens when bound to Major Histocompatibility Complex (MHC) or MHC class I-like molecules. Additionally, some αβTCRs can bind non-MHC molecules, but how much intact antigen reactivities are achieved remains unknown. Here, we identify an αβ T cell clone that directly recognises the intact foreign protein, R-phycoerythrin (PE), a multimeric (αβ)6γ protein complex. This direct αβTCR–PE interaction occurs in an MHC-independent manner, yet triggers T cell activation and bound PE with an affinity comparable to αβTCR–peptide–MHC interactions. The crystal structure reveals how six αβTCR molecules simultaneously engage the PE hexamer, mediated by the complementarity-determining regions (CDRs) of the αβTCR. Here, the αβTCR mainly binds to two α-helices of the globin fold in the PE α-subunit, which is analogous to the antigen-binding platform of the MHC molecule. Using retrogenic mice expressing this TCR, we show that it supports intrathymic T cell development, maturation, and exit into the periphery as mature CD4/CD8 double negative (DN) T cells with TCR-mediated functional capacity. Accordingly, we show how an αβTCR can recognise an intact foreign protein in an antibody-like manner.


  • Vγ9Vδ2 T cells recognize butyrophilin 2A1 and 3A1 heteromers

    by Thomas S. Fulford, Caroline Soliman, Rebecca G. Castle, Marc Rigau, Zheng Ruan, Olan Dolezal, Rebecca Seneviratna, Hamish G. Brown, Eric Hanssen, Andrew Hammet, et al.

    Butyrophilin (BTN) molecules are emerging as key regulators of T cell immunity; however, how they trigger cell-mediated responses is poorly understood. Here, the crystal structure of a gamma-delta T cell antigen receptor (γδTCR) in complex with BTN2A1 revealed that BTN2A1 engages the side of the γδTCR, leaving the apical TCR surface bioavailable. We reveal that a second γδTCR ligand co-engages γδTCR via binding to this accessible apical surface in a BTN3A1-dependent manner. BTN2A1 and BTN3A1 also directly interact with each other in cis, and structural analysis revealed formation of W-shaped heteromeric multimers. This BTN2A1–BTN3A1 interaction involved the same epitopes that BTN2A1 and BTN3A1 each use to mediate the γδTCR interaction; indeed, locking BTN2A1 and BTN3A1 together abrogated their interaction with γδTCR, supporting a model wherein the two γδTCR ligand-binding sites depend on accessibility to cryptic BTN epitopes. Our findings reveal a new paradigm in immune activation, whereby γδTCRs sense dual epitopes on BTN complexes.